Leaders in Retinal Metabolic Imaging

Developers of the

OcuMet Beacon


Developing technologies to detect eye disease earlier

OcuMet Beacon

Mitochondrial stress related to apoptotic cell death underlies pathology in a number of ocular diseases, including age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy. During apoptosis, mitochondria exhibit impaired electron transport in the respiratory chain, causing increased oxidation of flavoproteins. The balance between oxidized and reduced mitochondrial flavoproteins has been shown to reflect the overall health of the cell. Flavoprotein fluorescence (FPF) enables monitoring of the relative health of mitochondria through detection of oxidized flavoproteins. Oxidized flavoproteins emit green fluorescence when excited by blue light. FPF analysis quantifies the magnitude of this green fluorescence, which is a correlate of mitochondrial dysfunction.

The OcuMet Beacon is a novel medical device that is being developed to non-invasively assess retinal mitochondrial dysfunction. The OcuMet Beacon takes an infrared fundus image that highlights the acquisition area for the retinal metabolic image, takes a retinal flavoprotein fluorescence (FPF) metabolic image, and provides quantitative analysis and patient report printout. The patient report below is taken from a healthy, control eye.




2890 Carpenter Rd
Ann Arbor, MI 48108


(734) 205-5854


“An indication that a drug or intervention is working, or improving overall tissue metabolism, before structural changes become apparent, would be fantastic. I think this truly could be the next big leap in diagnosing, monitoring and treating retinal disease.”
— Richard Rosen, MD


Let's Chat.

Use the form below to contact us. We will get back to as quickly as we can.

For job opportunities, please email us your resume. We’re always looking for new and exceptional talent.

Name *